When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
HGEN - Gilead teams up with Humanigen in study of combo therapy for DLBCL
Humanigen Inc.
Gilead Sciences (GILD-1.7%) unit Kite Pharma will collaborate with Humanigen (OTCQB:HGEN+8.7%) on a Phase 1/2 clinical trial evaluating the combination of CAR T therapy Yescarta (axicabtagene ciloleucel) and lenzilumab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
More news on: Gilead Sciences, Inc., Humanigen, Inc., Healthcare stocks news,